New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions.
FDA makes it easier for biosimilars to obtain interchangeability designations
The FDA on Thursday began easing the process for biosimilar developers to demonstrate interchangeability with their brand-name biologics. The agency previously required studies to prove
June 21, 2024